Spring Bank Pharmaceuticals, Inc. (SBPH) Director David Arkowitz Purchases 2,500 Shares
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) Director David Arkowitz acquired 2,500 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $12.24 per share, with a total value of $30,600.00. Following the completion of the acquisition, the director now owns 17,086 shares in the company, valued at approximately $209,132.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Spring Bank Pharmaceuticals, Inc. (NASDAQ SBPH) traded down 0.15% during mid-day trading on Monday, hitting $13.00. 16,737 shares of the company traded hands. The stock’s market capitalization is $165.06 million. The company’s 50-day moving average is $14.44 and its 200-day moving average is $10.98. Spring Bank Pharmaceuticals, Inc. has a one year low of $6.31 and a one year high of $16.97.
A number of institutional investors have recently added to or reduced their stakes in the company. Private Capital Advisors Inc. boosted its position in Spring Bank Pharmaceuticals by 50.0% in the second quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock worth $762,000 after buying an additional 18,750 shares during the period. C WorldWide Group Holding A S bought a new position in Spring Bank Pharmaceuticals during the second quarter worth approximately $340,000. Parsons Capital Management Inc. RI boosted its position in Spring Bank Pharmaceuticals by 19.6% in the first quarter. Parsons Capital Management Inc. RI now owns 233,443 shares of the company’s stock worth $2,078,000 after buying an additional 38,278 shares during the period. Finally, Morse Asset Management Inc boosted its position in Spring Bank Pharmaceuticals by 156.9% in the second quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after buying an additional 38,900 shares during the period. 9.82% of the stock is owned by hedge funds and other institutional investors.
Several analysts recently issued reports on the stock. Chardan Capital decreased their price objective on shares of Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, August 1st. Cantor Fitzgerald assumed coverage on shares of Spring Bank Pharmaceuticals in a report on Wednesday, July 19th. They set an “overweight” rating and a $29.00 price objective for the company. ValuEngine raised shares of Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. Finally, JMP Securities assumed coverage on shares of Spring Bank Pharmaceuticals in a report on Friday, May 19th. They set a “market perform” rating and a $20.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $26.25.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.